Allogene Therapeutics, Inc. $ALLO Shares Acquired by Aberdeen Group plc

Aberdeen Group plc boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 82.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,582,265 shares of the company’s stock after acquiring an additional 715,015 shares during the quarter. Aberdeen Group plc owned 0.71% of Allogene Therapeutics worth $1,962,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ALLO. Quadrature Capital Ltd grew its stake in shares of Allogene Therapeutics by 29.6% in the second quarter. Quadrature Capital Ltd now owns 44,050 shares of the company’s stock worth $50,000 after purchasing an additional 10,059 shares in the last quarter. Brighton Jones LLC raised its stake in shares of Allogene Therapeutics by 81.6% during the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock valued at $31,000 after purchasing an additional 11,311 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Allogene Therapeutics by 19.6% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 85,720 shares of the company’s stock valued at $106,000 after purchasing an additional 14,032 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Allogene Therapeutics by 142.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock worth $35,000 after purchasing an additional 18,314 shares during the period. Finally, Cerity Partners LLC grew its position in Allogene Therapeutics by 5.2% in the 2nd quarter. Cerity Partners LLC now owns 400,267 shares of the company’s stock valued at $452,000 after buying an additional 19,843 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Down 3.8%

ALLO opened at $2.05 on Friday. The firm has a market cap of $460.70 million, a PE ratio of -2.09 and a beta of 0.60. The business has a fifty day simple moving average of $1.61 and a 200-day simple moving average of $1.36. Allogene Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.39.

Insider Buying and Selling

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 24,001 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total transaction of $42,241.76. Following the sale, the chief financial officer owned 1,252,795 shares in the company, valued at approximately $2,204,919.20. The trade was a 1.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Earl Martin Douglas sold 22,900 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total transaction of $40,304.00. Following the completion of the transaction, the senior vice president owned 564,948 shares of the company’s stock, valued at approximately $994,308.48. The trade was a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 215,855 shares of company stock worth $378,426. Company insiders own 13.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on ALLO shares. Citigroup upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Friday, January 9th. UBS Group assumed coverage on Allogene Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, Allogene Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.40.

Allogene Therapeutics Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.